(More on the USTR Special 301. link) Attached are links to several of the industry submissions for the 2021 USTR Special 301 list. The Docket: USTR-2020-0041 PhRMA 2021 Special 301 Review Comment, and Correction to Comment BIO 2021 Special 301… Continue Reading
PhRMA’s Special 301 submissions are part of a yearly ritual to shape the “Special 301” Report, an annual review of the global state of intellectual property rights (IPR) protection and enforcement, conducted by the Office of the United States Trade… Continue Reading
The following PDF file includes several email exchanges between Pfizer and USTR regarding Colombia’s accession to the Organisation for Economic Co-operation and Development (OECD). Pfizer proposed several conditions it wanted Colombia to agree to before the US would withdraw objections… Continue Reading
PhRMA and BIO have both requested that the US Trade Representative place the European Union on its watch list in the 2018 Special 301 Report. The Special 301 Report is a yearly review by the US Trade Representative of the… Continue Reading
On January 15, 2018, PhRMA provided comments on the Colombian Resolution 5246, a public interest declaration for several drugs for the hepatitis c virus (HCV). A copy of the PhRMA letter is attached below. It is a combination of complaints… Continue Reading
In a sternly worded letter dated 18 February 2016, the Biotechnology Innovation Organization (BIO), the National Association of Manufacturers (NAM), the National Foreign Trade Council (NFTC), the Pharmaceutical Research and Manufacturers of America (PhRMA), the U.S. Chamber of Commerce (the Chamber) and the United States Council for International Business (USCIB) wrote Senator Orrin Hatch (Republican – Utah) expressing serious reservations with the United Nations High-Level Panel on Access to Medicines (UN HLP). Continue Reading
PhRMA’s submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requests USTR classify India as a Priority Foreign Country citing the fact that India “continues to embrace these damaging policies, especially its IP rules, by publicly highlighting them… Continue Reading
While the GOP and Democratic conventions highlight the differences between the parties, there are some bipartisan issues, and one of the biggest is taking care of corporate interests.
From KEI staff review of Wikileaks cables (/wikileaks)
This cable signed by US Ambassador to Poland Victor H. Ashe provides a through and very tough critique of PhRMA’s submission to the 2009 Special 301 list. Ashe rejects every one of PhRMA’s main points, and explains why continually putting Poland on the Special 301 list is counter productive.
The following discusses the 2009 PhRMA submission for the USTR Special 301 list on Thailand. Thailand is one of three Asian countries (China, Philippines and Thailand) that were singled out by PhRMA for the harshest treatment. The submission on Thailand covers several topics, including these: